SPONSORED CONTENT
State-level oversight of the 340B Drug Pricing Program continues to expand. In 2025 alone, states including Colorado, Hawaii, Idaho, Indiana, Ohio, Rhode Island, and Vermont enacted laws requiring covered entities to report acquisition costs, reimbursement, and the use of 340B program savings. Earlier adopters—such as Maine, Minnesota, and Washington—have implemented similar reporting frameworks, though requirements and public transparency standards vary.
In this evolving landscape, community benefit statements are no longer optional storytelling tools—they are essential mechanisms for demonstrating how 340B savings translate into meaningful patient and community impact.
The most effective statements go beyond high-level financial summaries to deliver a structured, outcomes-focused narrative. High-quality examples consistently include quantifiable metrics, targeted investments in social determinants of health, direct patient financial assistance, care-access initiatives, and expansion of clinical pharmacy services. Incorporating concrete service examples—such as oncology or neurology support, medication access programs, transportation assistance, or nutrition services—helps clearly connect 340B savings to real-world improvements in access, quality, and outcomes.
Transparent, data-driven community benefit statements strengthen accountability and help regulators, policymakers, and the public understand the role of 340B in supporting underserved populations. Organizations with well-developed statements are often better positioned to demonstrate compliance readiness and strong program stewardship—regardless of whether state reporting is currently required.
As scrutiny of 340B continues to intensify, proactively developing a clear, evidence-based community benefit narrative is critical to sustaining confidence in the program and reinforcing its value to patients, providers, and communities.
Looking ahead: If your organization is reassessing how it documents and communicates 340B impact, expert guidance can help ensure your community benefit statement accurately describes your 340B use, is consistent and aligned with evolving expectations—today and in the years ahead.
Nadia Aldahiri is a Fellow at Visante. For questions, she can be reached at naldahiri@visante.com
